The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...

August 10, 2011 (Durham, North Carolina) — A major clinical trial showing that rivaroxaban (Xarelto, Bayer/Johnson & Johnson) is noninferior to dose-adjusted warfarin for the prevention of stroke or ...

Please provide your email address to receive an email when new articles are posted on . The BRAIN-AF trial enrolled adults younger than 65 years who had atrial fibrillation but no other risk factors ...

The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure. New data were announced from a phase 3 ...

PHILADELPHIA, PA—Rivaroxaban (Xarelto; Bayer/Janssen) is not the answer to the question of how best to treat patients after a successful TAVR, the full results of the prematurely stopped GALILEO trial ...

A new randomized trial lays the groundwork for the direct oral anticoagulant rivaroxaban (Xarelto; Janssen/Bayer) as a potential treatment option for children with venous thromboembolism (VTE). Its ...

Please provide your email address to receive an email when new articles are posted on . Acute left ventricular thrombus occurs in about 3% of all patients with STEMI. Rivaroxaban demonstrated similar ...

Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban ...

The RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm. Researchers ...

Rivaroxaban (Xarelto, Bayer) is indicated for the 'treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults'. For the ...